1. In Vivo
  2. >>Global Vision

All About Value – Olympus Medical Gets To Feel The NICE Effect

 
• By Ashley Yeo

The UK NICE HTA process can have a positive effect on medical device businesses even before a positive decision is made. That is the experience of surgery products innovator Olympus Medical Systems, a top-30 company globally that is laying down a marker in its approach to clinical and cost effectiveness.

Submitting the TURis (transurethral resection in saline) procedure for approval by the National Institute for Care Excellence (NICE) was not among Olympus Medical Systems Group’s initial UK plans for progressing the benign prostatic hyperplasia (BPH) treatment technology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By Ashley Yeo

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.

Financing Quarterly Statistics, Q1 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.